With a follow-up of 47 months, first-line pembrolizumab monotherapy significantly improved OS, RR, and PFS outcomes compared with platinum-based chemotherapy in patients with locally advanced/metastatic PD-L1-positive NSCLC without sensitizing EGFR/ALK alterations, with a manageable safety profile.[21] In light of these findings, the Food and Drug Administration (FDA) has approved pembrolizumab as a first-line treatment for PD-L1 ≥ 1% cancers (Fig. 1). Here, ALK is linked to non-small cell lung carcinoma.